Frederic Bost

INSERM U1065, C3M, 151 Route De St Antoine De Ginestière, BP2 3194, CEDEX 03, France Equipe 5
Nice, 06204, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Primary Cilium Forces Neuroendocrine Shift in Prostate Cancer through YAP1 Repression and Reduced Mitochondrial Activity.

Primary Cilium Forces Neuroendocrine Shift in Prostate Cancer through YAP1 Repression and Reduced Mitochondrial Activity.

Journal: Theranostics

Published: October 13, 2025

Prostate cancer and pollution: Dangerous connections.

Prostate cancer and pollution: Dangerous connections.

Journal: Annales d'endocrinologie

Published: May 08, 2025

Hypusination of the translation factor eIF5A regulates mitochondrial tRNA processing to promote prostate cancer aggressiveness.

Hypusination of the translation factor eIF5A regulates mitochondrial tRNA processing to promote prostate cancer aggressiveness.

Journal: Nature communications

Published: November 29, 2024

Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.

Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.

Journal: EMBO molecular medicine

Published: August 20, 2024

Development of a reliable, sensitive, and convenient assay for the discovery of new eIF5A hypusination inhibitors.

Development of a reliable, sensitive, and convenient assay for the discovery of new eIF5A hypusination inhibitors.

Journal: PloS one

Published: July 15, 2024

YAP1 modulation of primary cilia-mediated ciliogenesis in 2D and 3D prostate cancer models.

YAP1 modulation of primary cilia-mediated ciliogenesis in 2D and 3D prostate cancer models.

Journal: FEBS letters

Published: May 07, 2024

Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma.

Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma.

Journal: Cell death discovery

Published: March 24, 2024

HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.

HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.

Journal: Cell death discovery

Published: March 08, 2024

The marine-derived HIF-1α inhibitor, Yardenone 2, reduces prostate cancer cell proliferation by targeting HIF-1 target genes.

The marine-derived HIF-1α inhibitor, Yardenone 2, reduces prostate cancer cell proliferation by targeting HIF-1 target genes.

Journal: Cellular & molecular biology letters

Published: March 08, 2024

The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors.

The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors.

Journal: Cancer cell international

Published: November 07, 2023

HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.

HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.

Journal: bioRxiv : the preprint server for biology

Published: October 31, 2023

Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.

Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.

Journal: Molecular oncology

Published: August 16, 2023

Showing 1-12 of 56

Last Updated: 09/26/2026